These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19238633)

  • 21. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
    Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
    J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer.
    Wang S; An T; Duan J; Zhang L; Wu M; Zhou Q; Chen J; Zhuo M; Yang L; Wang Y; Bai H; Wang J
    PLoS One; 2013; 8(3):e51021. PubMed ID: 23520442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis.
    Rau KM; Chen HK; Shiu LY; Chao TL; Lo YP; Wang CC; Lin MC; Huang CC
    Int J Mol Sci; 2016 Apr; 17(4):524. PubMed ID: 27070580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
    Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
    J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.
    Lee S; Kim Y; Sun JM; Choi YL; Kim JG; Shim YM; Park YH; Ahn JS; Park K; Han JH; Ahn MJ
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1203-11. PubMed ID: 21626008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status.
    Badalian G; Barbai T; Rásó E; Derecskei K; Szendrôi M; Tímár J
    Pathol Oncol Res; 2007; 13(2):99-104. PubMed ID: 17607370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients.
    Ulivi P; Romagnoli M; Chiadini E; Casoni GL; Capelli L; Gurioli C; Zoli W; Saragoni L; Dubini A; Tesei A; Amadori D; Poletti V
    Int J Oncol; 2012 Jul; 41(1):147-52. PubMed ID: 22504767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.
    Krawczyk P; Ramlau R; Chorostowska-Wynimko J; Powrózek T; Lewandowska MA; Limon J; Wasąg B; Pankowski J; Kozielski J; Kalinka-Warzocha E; Szczęsna A; Wojas-Krawczyk K; Skroński M; Dziadziuszko R; Jaguś P; Antoszewska E; Szumiło J; Jarosz B; Woźniak A; Jóźwicki W; Dyszkiewicz W; Pasieka-Lis M; Kowalski DM; Krzakowski M; Jassem J; Milanowski J
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):61-8. PubMed ID: 25086987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
    Kim ST; Sung JS; Jo UH; Park KH; Shin SW; Kim YH
    Med Oncol; 2013 Mar; 30(1):328. PubMed ID: 23307237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.
    Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C
    Clin Lung Cancer; 2013 Sep; 14(5):581-91. PubMed ID: 23827517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotyping non-small cell lung cancer (NSCLC) in Latin America.
    Arrieta O; Cardona AF; Federico Bramuglia G; Gallo A; Campos-Parra AD; Serrano S; Castro M; Avilés A; Amorin E; Kirchuk R; Cuello M; Borbolla J; Riemersma O; Becerra H; Rosell R;
    J Thorac Oncol; 2011 Nov; 6(11):1955-9. PubMed ID: 22005474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
    Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
    J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
    Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas JJ; Monzo M
    Lung Cancer; 1994 Jul; 11(1-2):19-27. PubMed ID: 8081702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
    Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
    Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
    Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
    J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
    Kalikaki A; Koutsopoulos A; Hatzidaki D; Trypaki M; Kontopodis E; Stathopoulos E; Mavroudis D; Georgoulias V; Voutsina A
    Lung Cancer; 2010 Jul; 69(1):110-5. PubMed ID: 19854533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
    BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.